In hepatocellular carcinoma, studies have confirmed that knockdown of CPNE3 expression can enhance the sensitivity of hepatocellular carcinoma cells to the molecularly targeted drug sorafenib [16, 17]. This evidence concerns the gene CPNE3 and hepatocellular carcinoma.